HIV vaccine under development shows immune response

Experimental HIV vaccine induces extensive neutralizing antibodies in a small subset of volunteers in a Phase 1 study. Evidence suggests that a two-dose schedule eight weeks apart can elicit an immune response against human immunodeficiency virus.

The results of the clinical trial, published Thursday in the journal Science on World AIDS Day, provide a “clinical proof of concept” to support the development of booster regimens to induce an immune response against an HIV infection for which there is no cure and which can cause acquired immunodeficiency syndrome. . known as AIDS.